[go: up one dir, main page]

AU2001284645A1 - Quinuclidine-substituted aryl compounds for treatment of disease - Google Patents

Quinuclidine-substituted aryl compounds for treatment of disease

Info

Publication number
AU2001284645A1
AU2001284645A1 AU2001284645A AU8464501A AU2001284645A1 AU 2001284645 A1 AU2001284645 A1 AU 2001284645A1 AU 2001284645 A AU2001284645 A AU 2001284645A AU 8464501 A AU8464501 A AU 8464501A AU 2001284645 A1 AU2001284645 A1 AU 2001284645A1
Authority
AU
Australia
Prior art keywords
quinuclidine
disease
treatment
substituted aryl
aryl compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284645A
Inventor
Vincent E. Groppi Jr.
Jason K. Myers
David W. Piotrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2001284645A1 publication Critical patent/AU2001284645A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001284645A 2000-08-18 2001-08-17 Quinuclidine-substituted aryl compounds for treatment of disease Abandoned AU2001284645A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22616400P 2000-08-18 2000-08-18
US60226164 2000-08-18
US28495601P 2001-04-19 2001-04-19
US28497101P 2001-04-19 2001-04-19
US28496801P 2001-04-19 2001-04-19
US60284968 2001-04-19
US60284971 2001-04-19
US60284956 2001-04-19
PCT/US2001/021136 WO2002016356A2 (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)

Publications (1)

Publication Number Publication Date
AU2001284645A1 true AU2001284645A1 (en) 2002-03-04

Family

ID=27499421

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284645A Abandoned AU2001284645A1 (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl compounds for treatment of disease

Country Status (3)

Country Link
US (1) US6492386B2 (en)
AU (1) AU2001284645A1 (en)
WO (1) WO2002016356A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2003032897A2 (en) * 2001-10-16 2003-04-24 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
ES2269975T3 (en) * 2002-02-21 2007-04-01 Aprea Ab USE OF LOW-MOLECULAR WEIGHT COMPOUNDS TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DISEASES MEDIATED BY P53 MUTANT.
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
ATE378048T1 (en) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res INHIBITION OF INFLAMMATION USING ALPHA-7 RECEPTOR-LINKING CHOLINERGIC AGONISTS
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
EP1638560A1 (en) 2003-06-20 2006-03-29 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
JP2007538046A (en) * 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ Novel azabicycloaryl derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
JP2009506037A (en) 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド Heteroaryl-substituted diazatricycloalkanes, methods for their preparation and methods for their use
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use
CN104193741B (en) 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 Quinuclidine-4-ylmethyl 1H-indole-3-carboxylic acid ester derivant as alpha 7 nicotinic acetylcholine receptor ligands
WO2009102962A2 (en) 2008-02-13 2009-08-20 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
KR20140146216A (en) 2008-11-19 2014-12-24 포럼 파마슈티칼즈 인크. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX2011011972A (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors.
PL3029039T3 (en) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
CN103183625B (en) * 2011-12-28 2015-07-08 四川大学 Anti-HIV compound and preparation method and application thereof
HK1208356A1 (en) 2012-05-08 2016-03-04 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
MA37975B2 (en) 2012-09-11 2021-03-31 Genzyme Corp Glucosylceramide synthase inhibitors
TW201617342A (en) 2014-07-11 2016-05-16 阿法馬根公司 Quinuclidines for modulating alpha 7 activity
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
PT3920912T (en) 2019-02-04 2025-09-09 Genzyme Corp Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
CN115427038A (en) 2020-02-03 2022-12-02 建新公司 Methods of treating nervous system symptoms associated with lysosomal storage diseases
MX2023001014A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical compositions comprising venglustat.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237066A (en) * 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
GB9027487D0 (en) * 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
US5741819A (en) * 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
SE9600683D0 (en) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
SE9903760D0 (en) * 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (en) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (en) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
US20020052389A1 (en) 2002-05-02
WO2002016356A2 (en) 2002-02-28
WO2002016356A3 (en) 2002-05-16
US6492386B2 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
AU2001282873A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
AU2001284645A1 (en) Quinuclidine-substituted aryl compounds for treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2001284646A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
HUP0203803A3 (en) Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
AU2935200A (en) Compounds for the treatment of obesity
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2002227958A1 (en) Use of moulding compounds for producing treatment devices
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
AU8322401A (en) Indole compounds useful for the treatment of cancer
AU2002303145A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU2002341485A1 (en) Treatment of polyaluminium compounds
AU2000272704A1 (en) Use of compounds for the treatment of obesity